TPD | Jotup

Plug Announces First Quarter 2024 Financial Results

Retrieved on:

星期四, 五月 9, 2024

LATHAM, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG) (the “Company”), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, announced its financial results and operational milestones for the first quarter of 2024.

Key Points:

LATHAM, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG) (the “Company”), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, announced its financial results and operational milestones for the first quarter of 2024.
Earnings-Per-Share (EPS) and Revenue: The Company reported revenue of $120.3 million and EPS loss of $0.46 for the quarter ended March 31, 2024.
Consistently with past seasonality and continued new product scaling, Plug expects that one-third of its full year revenue will be in the first half of 2024.
As of the Q1 2024 earnings date, Plug currently has 20 electrolyzer systems undergoing commissioning at third-party customer sites, with further deliveries to be made over the balance of 2024.

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Retrieved on:

星期三, 五月 8, 2024

Bank of America, News, Conference, BofA Securities, TPD, Therapy

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Key Points:

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; and
TD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m.
ET.
Live webcasts of the presentations will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
Replays of the webcasts will be archived and available following the events.

Plug Signs MOU with Allied Green Ammonia for 3GW of Electrolyzer Supply at World-Class Green Ammonia Production Facility

Retrieved on:

星期五, 五月 3, 2024

Hydrogen, MOU, Natural gas, Electricity, Steam, Carbon, SMR, Oxygen, FID, Ammonia, PEM, TPD, Electrolysis

Following the MOU, Plug and AGA plan to enter an agreement, as outlined in the MOU, to initiate a Basic Engineering and Design Package (BEDP) for the 3GW capacity project.

Key Points:

Following the MOU, Plug and AGA plan to enter an agreement, as outlined in the MOU, to initiate a Basic Engineering and Design Package (BEDP) for the 3GW capacity project.
“Ammonia producers have recognized the substantial advantages of cost and carbon reduction through electrolysis-based hydrogen,” said Plug CEO Andy Marsh.
AGA’s production facility will operate a 2500 metric ton-per-day (TPD) green ammonia process.
The facility is geographically positioned to meet AGA’s intended customers’ growing needs, providing them with a reliable and secure supply of green ammonia from the region.

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

Retrieved on:

星期四, 四月 25, 2024

News, Webcast, TPD, International, Therapy

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m.

Key Points:

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m.
To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.
A live webcast of the Company’s conference call will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
A replay of the webcast will be archived and available following the event.

Plug Continues to Make Substantial Advancement in Hydrogen Generation Buildout

Retrieved on:

星期二, 四月 23, 2024

Proton, EnergySolutions, Olin Corporation, Hydrogen, Proton-exchange membrane, PEM, TPD, Growth, Joint

LATHAM, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has reached nameplate capacity at the company’s hydrogen plants in Georgia and Tennessee. With this increased supply from our hydrogen production network, Plug will benefit from a lower cost of hydrogen, a crucial step in the company’s roadmap to achieve profitable growth. This is headlined by the company’s first green hydrogen plant in Georgia already reaching nameplate capacity of 15 tons per day (TPD) of liquid hydrogen production, marking a significant milestone for Plug’s hydrogen network and the hydrogen economy in the U.S.

Key Points:

Recalibrated hydrogen pricing continues to make solid progress, underscoring strategic nature of Plug’s customer relationships
LATHAM, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has reached nameplate capacity at the company’s hydrogen plants in Georgia and Tennessee.
With this increased supply from our hydrogen production network, Plug will benefit from a lower cost of hydrogen, a crucial step in the company’s roadmap to achieve profitable growth.
Plug has continued to make substantial progress on building out its North America green hydrogen network to meet customer demand.
In addition, the company continues to collaborate with its key hydrogen supplier in the U.S. Plug is doing substantial work on other U.S.-based plants and is actively engaged with key strategic suppliers to facilitate the expansion of its green hydrogen network and to achieve cost-effectiveness in green hydrogen production at scale.

Sheppard Mullin Welcomes IP Partner Alex Chung in Washington D.C.

Retrieved on:

星期三, 四月 24, 2024

Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Kwan-Ho “Alex” Chung, Ph.D. has joined the firm’s Intellectual Property practice group and Life Sciences industry team in Washington, D.C. Chung was most recently a partner at Perkins Coie LLP.

Key Points:

Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Kwan-Ho “Alex” Chung, Ph.D. has joined the firm’s Intellectual Property practice group and Life Sciences industry team in Washington, D.C. Chung was most recently a partner at Perkins Coie LLP.
Chung’s move to Sheppard Mullin follows the recent hire of life sciences IP partner, Jaime Choi , Ph.D., in February.
His extensive experience includes procuring, managing, evaluating, enforcing and defending patents and providing clients strategic IP counsel.
“Alex is another pillar in our strategic effort to continue to grow our Life Sciences team,” said Luca Salvi, chair of Sheppard Mullin.

Nowcasting consumer price inflation using high-frequency scanner data: evidence from Germany

Retrieved on:

星期二, 四月 23, 2024

Consensus, Online, Cream, Honey, Tax, Glass, MAPI, Consensus Economics, Journal of Economic Perspectives, Milk, Shower, Low-alcohol beer, Autoregressive–moving-average model, Infant, C3, Islam, Wine, Core inflation, Research Papers in Economics, National accounts, Kálmán, Barcode, Journal of International Economics, Communication, Royal Statistical Society, COVID19, Kohl (cosmetics), Natural disaster, Business, Observation, Paper, VAT, European Economic Review, Diebold Nixdorf, Blancmange, Calendar, Sunflower oil, Annual Review of Economics, Hand, C4, DESTATIS, NBER, Tinning, Razor, Forecasting, Gasoline, Coffee, European Economic Association, Cat, Journal of Monetary Economics, Journal of Applied Econometrics, Medeiros, Architecture, Oxford University Press, Producer, GfK, Quarterly Journal of Economics, Margarine, NCBS, Starch, Political economy, Consistency, COVID-19, Consensus decision-making, Website, MIDAS, Behavior, Deutsche Bundesbank, PPI, World Bank, Collection, Medical classification, Orange, Eurozone, Butter, FMCG, Noise, Travel, Clothing, History, Inflation, Liver, International economics, Journal of Political Economy, BSI, OLS, Statistics, Consumer, PDF, University of Chicago, Classification, ECB, Fats, Policy, Multi, WOB, Outline, C6, Mincing, Canadian International Council, Social science, Perfume, University of California, Berkeley, Journal of Forecasting, Federal Reserve Bank, JEL, L1, Journal, Research, Candle, Food, TPD, Credit, Spice, LPG, Janssen, Marmalade, Superior, Literature, Chocolate, Beef, Kiel University, European Central Bank, Natural gas, HICP, Monetary economics, Yogurt, Section 5, ILO, Bermingham, Price, GTIN, Cheese, Macroeconomics, Growth, Beck, XJ, Government, De Beer, Supermarket, Ice cream, Naturally, C53, Corn flakes, BIS, Biscuit, LASSO, Petroleum, A.2, Poultry, Accuracy and precision, Application, White, Lettuce, Risk, ESCB, University of Siegen, OECD, Chapter One, Lipstick, Sack, XT, BIC, Garlic, Consumption, Sokol, Meat, VAR, Database, Section 3, Rusk, American Economic Journal, Royal, Curd, Overalls, Lamb, Great Lockdown, Fruit, Economy, COICOP, International Journal of Forecasting, Aftershave, Section 2, Nonparametric statistics, Attention, Conference, CPI, Heat, Public economics, Common sunflower, Nowcasting, American Economic Review, Computational Statistics (journal), GFK, COVID-19 pandemic, Exercise, Shock, Running, UNECE, Edible, Gambling, Banco, Rigid transformation, European Commission, Frozen, C.2, PRISMA, Official statistics, Concept, Drink, Transaction data, Somatosensory system, Punctuality, Altbier, Food prices, Response, GDP, Index, E31, Cabinet of Germany, Holiday, Machine learning, Series, Green, Whisky, Vegetable, Cola, Journal of Econometrics, Sadik Harchaoui, University, Aggregate, World Bank Group, B.1, Use, Book, Economic statistics, Civil service commission, 1L, Apple, Bread, Filter, Central bank, Brandeis University, Economic Modelling, Bank, Barkan, Roulade, Dairy product, Neural network, Reproduction, IMF, Section, ID, Data, D4L, Cryptocurrency

Key Points:

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on:

星期一, 四月 8, 2024

MDM2, Apoptosis, ASH, Drug discovery, PD, Patient, Tumor microenvironment, Cancer, Doctor of Philosophy, TPD, Proteomics, AACR, Society, Therapy, Drug development, Downregulation and upregulation, VHL, STAT3, Pharmaceutical industry

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company’s unique target selection strategy and strong preclinical to clinical translation observed across the Company’s first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.

Key Points:

For these reasons, STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies.
Additionally, this unique mechanism of action led to induction of proinflammatory anti-tumorigenic transcriptional signatures in the tumor microenvironment.
This has resulted in robust antitumor activity in patients, as reported in the Company’s latest clinical update at the American Society of Hematology (ASH) Annual Meeting in December 2023.
The Company expects to complete both studies and share additional clinical data to inform the programs’ next development steps in 2024 at upcoming medical meetings.

Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors

Retrieved on:

星期三, 三月 27, 2024

Research, TPD, Cannabis, Investor's Business Daily, OTC, HYLA, CAVE, BBC World Service, Drug

This initiative is set to position EDXC and its HYLA division at the forefront of the rapidly evolving cannabis and plant-based wellness landscapes.

Key Points:

This initiative is set to position EDXC and its HYLA division at the forefront of the rapidly evolving cannabis and plant-based wellness landscapes.
The landmark legalization of cannabis in Germany, highlighted by Investor's Business Daily, heralds a transformative era in the European market, ushering in unparalleled opportunities for forward-thinking companies like Endexx Corporation.
Moreover, Endexx Corporation has commenced TPD registration in Europe, further cementing its market presence and paving the way for expanded distribution throughout the continent.
With a commitment to sustainability, wellness, and innovation, Endexx Corporation invests in research and development, strategic marketing, and global expansion efforts to leverage evolving market dynamics and regulatory landscapes.

Nu:ionic Hydrogen-Producing Microwave Reactor Achieves Commercial Threshold

Retrieved on:

星期二, 三月 26, 2024

This commercial scale, 100kW electrified reactor can be used in many applications for low carbon hydrogen production from various feedstocks, including biogas, natural gas or renewable ammonia.

Key Points:

This commercial scale, 100kW electrified reactor can be used in many applications for low carbon hydrogen production from various feedstocks, including biogas, natural gas or renewable ammonia.
The reactor is undergoing rigorous testing and accumulating run time in the company’s Fredericton, New Brunswick Research and Innovation Center.
Microwave Catalytic Reformer installation at Nu:ionic’s Research and Innovation Center.
The Microwave Catalytic Reformer is an example of an innovative use of industrial microwave technology for natural gas reforming and other applications,” said Jim Tranquilla, President and Chief Technology Officer.